In 2018, approximately 22,240 new cases of ovarian cancer and 14,070 deaths from ovarian cancer are expected in the United States. The American Cancer Society provides an overview of ovarian cancer incidence and mortality based on data from nationwide population-based cancer registries and the National Center for Health Statistics. Ovarian cancer incidence rates have declined from 16.6 per 100,000 in 1985 to 11.8 per 100,000 in 2014, and mortality rates have decreased from 10.0 per 100,000 in 1976 to 6.7 per 100,000 in 2015. Ovarian cancer is a heterogeneous group of malignancies, with 90% being epithelial cancers, primarily serous carcinomas. Racial/ethnic disparities exist, with non-Hispanic whites (NHWs) having the highest incidence and mortality rates, while non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) have the lowest. APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages. Most serous carcinomas are diagnosed at advanced stages, with 5-year survival rates of 42% for stage III and 26% for stage IV. APIs have the highest 5-year survival rate for all stages of epithelial cancer, while NHBs have the lowest. Progress in reducing ovarian cancer incidence and mortality can be accelerated by addressing racial disparities and advancing understanding of etiology and tumorigenesis.In 2018, approximately 22,240 new cases of ovarian cancer and 14,070 deaths from ovarian cancer are expected in the United States. The American Cancer Society provides an overview of ovarian cancer incidence and mortality based on data from nationwide population-based cancer registries and the National Center for Health Statistics. Ovarian cancer incidence rates have declined from 16.6 per 100,000 in 1985 to 11.8 per 100,000 in 2014, and mortality rates have decreased from 10.0 per 100,000 in 1976 to 6.7 per 100,000 in 2015. Ovarian cancer is a heterogeneous group of malignancies, with 90% being epithelial cancers, primarily serous carcinomas. Racial/ethnic disparities exist, with non-Hispanic whites (NHWs) having the highest incidence and mortality rates, while non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) have the lowest. APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages. Most serous carcinomas are diagnosed at advanced stages, with 5-year survival rates of 42% for stage III and 26% for stage IV. APIs have the highest 5-year survival rate for all stages of epithelial cancer, while NHBs have the lowest. Progress in reducing ovarian cancer incidence and mortality can be accelerated by addressing racial disparities and advancing understanding of etiology and tumorigenesis.